Product Images Venlafaxine Hydrochloride

This is a description for Major brand Venlafaxine Hydrochloride extended-release capsules in 150 mg strength with NDC number 0904-6470-61. It is a prescription-only medication with 100 capsules per package. The drug information, dosage, and administration details are not available. The drug is intended for "situations Use Oy" and is printed and manufactured by Major Pharmaceuticals.*

This is a medication packaging for Venlafaxine Hydrochloride Extended-Release capsules. Each capsule contains a certain amount of the active ingredient. There are warnings and precautionary information available in the enclosed medication guide, which should be dispensed by the pharmacist. The medication should be stored between 20-25C and out of reach of children. This is for prescription use only. The text also lists the product's NDC number, the unit dose, and the manufacturer's information.*

This is a description of a medication named Venlafaxine Hydrochloride Extended-Release Capsules, USP with a National Drug Code of 0904-6468-61. The medication comes in a unit dose form and is only available through a prescription. The package contains 100 capsules. The rest of the information seems to be a combination of garbled text and random characters, making it not usable.*

This text seems to contain a list of interacting drugs including "emanal", "Dlazspam", "Ketosonszole", "Ketosonszals", "wotopror", "imipramine", and "Litnam". It also provides recommendations on the use of drugs such as caution in patients with hypertension or liver dysfunction, and monitoring of blood pressure. However, the last line "152 253 g ki b0 S veOIRCE" is not readable and therefore, the description cannot be completed.*

This text appears to be a table or chart with recommendations for dose adjustments based on specific population analytes such as hepatic or renal impairment, age and gender. The table indicates the specific analyte being evaluated and recommends reducing or increasing the dose by a certain percentage, along with additional recommendations such as the need for dosing individualization or close monitoring.*